Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCND3 | P30281 | 17/20 | 0.52 |
| ▸ | CDK6 | Q00534 | 17/20 | 0.52 |
| ▸ | CDK4 | P11802 | 14/20 | 0.52 |
| ▸ | CCND1 | P24385 | 13/20 | 0.52 |
| ▸ | CDK9 | P50750 | 11/20 | 0.52 |
| ▸ | CCNT1 | O60563 | 7/20 | 0.52 |
| ▸ | CDK7 | P50613 | 4/20 | 0.52 |
| ▸ | CCNH | P51946 | 4/20 | 0.52 |
| ▸ | MNAT1 | P51948 | 2/20 | 0.52 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.52 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.52 |
| ▸ | JAK2 | O60674 | 1/20 | 0.51 |
| ▸ | EGFR | P00533 | 1/20 | 0.51 |
| ▸ | JAK3 | P52333 | 1/20 | 0.51 |
| ▸ | CCNA2 | P20248 | 9/20 | 0.51 |
| ▸ | CDK2 | P24941 | 9/20 | 0.51 |
| ▸ | CDK1 | P06493 | 4/20 | 0.51 |
| ▸ | CCNB1 | P14635 | 3/20 | 0.51 |
| ▸ | CCNE1 | P24864 | 4/20 | 0.50 |
| ▸ | CCNK | O75909 | 4/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23906670 | 1.00 | CCND3 (0.52) | CCND3CDK6CDK4CCND1CDK9 | |
| SCHEMBL30086476 | 0.90 | CDK4 (0.51) | CCND3CDK6CDK4CCND1CDK9 | |
| SCHEMBL30086727 | 0.90 | CDK4 (0.57) | CCND3CDK6CDK4CCND1CDK9 | |
| SCHEMBL23906230 | 0.90 | CDK4 (0.51) | CCND3CDK6CDK4CCND1CDK9 | |
| SCHEMBL23887682 | 0.90 | CDK4 (0.57) | CCND3CDK6CDK4CCND1CDK9 | |
| SCHEMBL23906886 | 0.88 | JAK2 (0.66) | CDK4JAK2EGFRJAK3CDK2 | |
| SCHEMBL30086423 | 0.88 | JAK2 (0.66) | CDK4JAK2EGFRJAK3CDK2 | |
| SCHEMBL23906595 | 0.85 | JAK2 (0.61) | CDK9CCNT1CDK7CCNHMNAT1 | |
| SCHEMBL30086477 | 0.85 | JAK2 (0.61) | CDK9CCNT1CDK7CCNHMNAT1 | |
| SCHEMBL23906844 | 0.81 | JAK2 (0.64) | CDK4JAK2EGFRJAK3CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230399312-A1 | SUBSTITUTED PYRIMIDINES AND METHODS OF USE | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-12-14 | — | — | US | disclosed |
| US-11673879-B2 | Substituted pyrimidines and methods of use | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-06-13 | — | — | US | disclosed |
| US-20220372015-A1 | SUBSTITUTED PYRIMIDINES AND METHODS OF USE | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220372015-A1 | SUBSTITUTED PYRIMIDINES AND METHODS OF USE | ALK, TYMP, ENTPD5 | CCND3 3288/4885CDK6 291/4885CDK4 937/4885 |
| US-11673879-B2 | Substituted pyrimidines and methods of use | ALK, TYMP, ENTPD5 | CCND3 3288/4885CDK6 291/4885CDK4 937/4885 |
| US-20230399312-A1 | SUBSTITUTED PYRIMIDINES AND METHODS OF USE | ALK, TYMP, ENTPD5 | CCND3 3288/4885CDK6 291/4885CDK4 937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.